Careside Inc (NASDAQ:CASI) 2017 Q4 Sentiment Report

April 22, 2018 - By wolcottdaily

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Logo

Sentiment for Careside Inc (NASDAQ:CASI)

Careside Inc (NASDAQ:CASI) institutional sentiment increased to 1.9 in Q4 2017. Its up 0.76, from 1.14 in 2017Q3. The ratio is positive, as 19 institutional investors increased or opened new holdings, while 10 reduced and sold their positions in Careside Inc. The institutional investors in our partner’s database now have: 3.56 million shares, up from 2.39 million shares in 2017Q3. Also, the number of institutional investors holding Careside Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 3 Reduced: 7 Increased: 8 New Position: 11.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $545.55 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

The stock decreased 0.58% or $0.04 during the last trading session, reaching $6.85. About 793,803 shares traded or 34.30% up from the average. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 181.56% since April 22, 2017 and is uptrending. It has outperformed by 170.01% the S&P500.

Analysts await CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report earnings on May, 21. They expect $-0.07 earnings per share, down 133.33 % or $0.04 from last year’s $-0.03 per share. After $-0.08 actual earnings per share reported by CASI Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -12.50 % EPS growth.

Wellington Shields & Co. Llc holds 0.78% of its portfolio in CASI Pharmaceuticals, Inc. for 445,118 shares. Wellington Shields Capital Management Llc owns 725,348 shares or 0.37% of their US portfolio. Moreover, Alpine Global Management Llc has 0.02% invested in the company for 27,729 shares. The Massachusetts-based Moors & Cabot Inc. has invested 0.01% in the stock. Perceptive Advisors Llc, a New York-based fund reported 83,682 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.